EDIT
Editas Medicine Inc (EDIT)
Healthcare • NASDAQ • $2.80+1.45%
- Symbol
- EDIT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.80
- Daily Change
- +1.45%
- Market Cap
- $412.81M
- Trailing P/E
- N/A
- Forward P/E
- -2.87
- 52W High
- $4.54
- 52W Low
- $1.66
- Analyst Target
- $5.78
- Dividend Yield
- N/A
- Beta
- 2.10
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Geng…
Company websiteResearch EDIT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.